
Kallum Titchmarsh
Stock Analyst at Morgan Stanley
(4.57)
# 1,003
Out of 5,136 analysts
230
Total ratings
66.7%
Success rate
16%
Average return
Main Sectors:
Stocks Rated by Kallum Titchmarsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Reiterated: Buy | $200 | $144.03 | +38.86% | 9 | Oct 20, 2026 | |
| A Agilent Technologies | Rated: Buy | $175 → $190 | $172.92 | +9.88% | 9 | Oct 13, 2026 | |
| ADPT Adaptive Biotechnologies | Reiterated: Hold | $27 | $27.87 | -3.12% | 7 | Oct 13, 2026 | |
| AVTR Avantor | Rated: Hold | $14 → $15 | $15.32 | -2.09% | 3 | Oct 13, 2026 | |
| CRL Charles River Laboratories International | Rated: Buy | $300 → $340 | $335.52 | +1.34% | 10 | Oct 13, 2026 | |
| DHR Danaher | Rated: Buy | $220 → $240 | $229.91 | +4.39% | 10 | Oct 13, 2026 | |
| GRAL GRAIL | Reiterated: Hold | $120 | $105.60 | +13.64% | 9 | Oct 13, 2026 | |
| NTRA Natera | Rated: Buy | $355 → $435 | $288.48 | +50.79% | 8 | Oct 13, 2026 | |
| TMO Thermo Fisher Scientific | Rated: Buy | $650 → $730 | $691.33 | +5.59% | 6 | Oct 13, 2026 | |
| TXG 10x Genomics | Rated: Hold | $40 → $70 | $54.99 | +27.30% | 8 | Oct 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5.5 → $5 | $5.63 | -11.19% | 4 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1,450 → $1,575 | $1,727.26 | -8.82% | 6 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $20 | $15.53 | +28.78% | 16 | Oct 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $365 → $400 | $417.80 | -4.26% | 11 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 → $21 | $18.65 | +12.60% | 4 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $240 → $270 | $264.73 | +1.99% | 7 | Sep 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $430 | $453.42 | -5.17% | 6 | Sep 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $35 → $40 | $46.86 | -14.64% | 2 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Sell | $47 → $44 | $24.01 | +83.26% | 6 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $64.76 | +8.09% | 5 | Jul 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $9 → $13 | $14.80 | -12.16% | 4 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $68 | $70.50 | n/a | 6 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $182 | $59.12 | n/a | 12 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 → $160 | $90.83 | n/a | 15 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $15 | $6.25 | n/a | 11 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $4.42 | n/a | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $23.41 | n/a | 3 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $260 | $320.62 | n/a | 12 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 → $11 | $6.78 | n/a | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4 | $10.59 | n/a | 14 | Dec 3, 2024 |
Guardant Health
Oct 20, 2026
Reiterated: Buy
Price Target: $200
Current: $144.03
Upside: +38.86%
Agilent Technologies
Oct 13, 2026
Rated: Buy
Price Target: $175 → $190
Current: $172.92
Upside: +9.88%
Adaptive Biotechnologies
Oct 13, 2026
Reiterated: Hold
Price Target: $27
Current: $27.87
Upside: -3.12%
Avantor
Oct 13, 2026
Rated: Hold
Price Target: $14 → $15
Current: $15.32
Upside: -2.09%
Charles River Laboratories International
Oct 13, 2026
Rated: Buy
Price Target: $300 → $340
Current: $335.52
Upside: +1.34%
Danaher
Oct 13, 2026
Rated: Buy
Price Target: $220 → $240
Current: $229.91
Upside: +4.39%
GRAIL
Oct 13, 2026
Reiterated: Hold
Price Target: $120
Current: $105.60
Upside: +13.64%
Natera
Oct 13, 2026
Rated: Buy
Price Target: $355 → $435
Current: $288.48
Upside: +50.79%
Thermo Fisher Scientific
Oct 13, 2026
Rated: Buy
Price Target: $650 → $730
Current: $691.33
Upside: +5.59%
10x Genomics
Oct 13, 2026
Rated: Hold
Price Target: $40 → $70
Current: $54.99
Upside: +27.30%
Oct 9, 2026
Reiterated: Hold
Price Target: $5.5 → $5
Current: $5.63
Upside: -11.19%
Oct 9, 2026
Reiterated: Hold
Price Target: $1,450 → $1,575
Current: $1,727.26
Upside: -8.82%
Oct 5, 2026
Rated: Hold
Price Target: $20
Current: $15.53
Upside: +28.78%
Sep 22, 2026
Upgraded: Buy
Price Target: $365 → $400
Current: $417.80
Upside: -4.26%
Sep 18, 2026
Rated: Buy
Price Target: $19 → $21
Current: $18.65
Upside: +12.60%
Sep 17, 2026
Rated: Hold
Price Target: $240 → $270
Current: $264.73
Upside: +1.99%
Sep 14, 2026
Reiterated: Hold
Price Target: $430
Current: $453.42
Upside: -5.17%
Aug 17, 2026
Reiterated: Hold
Price Target: $35 → $40
Current: $46.86
Upside: -14.64%
Aug 4, 2026
Rated: Sell
Price Target: $47 → $44
Current: $24.01
Upside: +83.26%
Jul 10, 2026
Reiterated: Buy
Price Target: $70
Current: $64.76
Upside: +8.09%
Jul 9, 2026
Rated: Hold
Price Target: $9 → $13
Current: $14.80
Upside: -12.16%
Jul 15, 2025
Reiterated: Buy
Price Target: $100 → $68
Current: $70.50
Upside: n/a
Jul 15, 2025
Reiterated: Buy
Price Target: $200 → $182
Current: $59.12
Upside: n/a
Jun 11, 2025
Reiterated: Buy
Price Target: $130 → $160
Current: $90.83
Upside: n/a
May 20, 2025
Reiterated: Hold
Price Target: $20 → $15
Current: $6.25
Upside: n/a
May 9, 2025
Reiterated: Hold
Price Target: $10
Current: $4.42
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: $19
Current: $23.41
Upside: n/a
Apr 24, 2025
Reiterated: Hold
Price Target: $260
Current: $320.62
Upside: n/a
Feb 27, 2025
Reiterated: Hold
Price Target: $10 → $11
Current: $6.78
Upside: n/a
Dec 3, 2024
Reiterated: Hold
Price Target: $5 → $4
Current: $10.59
Upside: n/a